Nanoparticle-Mediated Delivery of STAT3 Inhibitors in the Treatment of Lung Cancer
Lung cancer is a common malignancy worldwide, with high morbidity and mortality. Signal transducer and activator of transcription 3 (STAT3) is an important transcription factor that not only regulates different hallmarks of cancer, such as tumorigenesis, cell proliferation, and metastasis but also r...
Main Authors: | Qiyi Feng, Kai Xiao |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-12-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/14/12/2787 |
Similar Items
-
Nanoparticles Targeting STATs in Cancer Therapy
by: Milad Ashrafizadeh, et al.
Published: (2019-09-01) -
The use of nanoparticles for targeted drug delivery in non-small cell lung cancer
by: Jessica E. Holder, et al.
Published: (2023-03-01) -
Monoclonal antibody as a targeting mediator for nanoparticle targeted delivery system for lung cancer
by: Nasrul Wathoni, et al.
Published: (2022-12-01) -
Oligonucleotide-Based Therapeutics for STAT3 Targeting in Cancer—Drug Carriers Matter
by: Sara Molenda, et al.
Published: (2023-11-01) -
Unveiling the potential effects of resveratrol in lung cancer treatment: Mechanisms and nanoparticle-based drug delivery strategies
by: Behnam Najafiyan, et al.
Published: (2024-03-01)